What are the primary barriers to clozapine utilization in the United States, and how do these barriers impact patient care? What are some common misconceptions or negative attitudes among prescribers regarding clozapine, and how can these be addressed? What are some effective strategies for improving the management of clozapine’s side effects to encourage its use? What strategies can be implemented to improve education and awareness about clozapine?

Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on underutilized psychotropic drugs.

Today, Dr. Andy Cutler interviews Dr. Jonathan Meyer and Dr. Stephen Stahl about factors that have led to the underutilization of clozapine in psychiatry.

Let’s listen to Part 3 of our theme: Underutilized Psychiatric Drugs.

Subscribe to the NEI Podcast, so that you don’t miss another episode!

Resources

The Clozapine Handbook

Clozapine titrations paper (see Supplementary Material):

de Leon J et al. Pharmacopsychiatry 2022;55(2):73-86.

FDA committees meeting to discuss reevaluation of the Clozapine REMS program (November 19, 2024): click here.

E232 - The PsychopharmaStahlogy Show: Underutilized Psychiatric Drugs: Clozapine with Dr. Jonathan Meyer 52:29 Share

NEI Podcast

Shownotes Transcript

E232 - The PsychopharmaStahlogy Show: Underutilized Psychiatric Drugs: Clozapine with Dr. Jonathan Meyer